Table 2.
Pooled Eradication Rates From Selected Studies
| Grouped therapies | ||||||
|---|---|---|---|---|---|---|
| Treatment | All countries |
Western countries |
North America |
|||
| Na | Pooledb, % (95% CI) | Na | Pooledb, % (95% CI) | Na | Pooledb, % (95% CI) | |
| Vonoprazan-based triple therapy | 5 | 89.6 (84.1, 93.3) | 1 | 80.1 (76.2, 84.6) | 1 | 80.1 (76.2, 84.6) |
| Vonoprazan dual therapy | 2 | 80.3 (74.5, 85.1) | 1 | 77.2 (72.3, 81.4) | 1 | 77.2 (72.3, 81.4) |
| PPI-based triple therapy | 14 | 73.2 (64.5, 80.3) | 7 | 80 (68.9, 87.5) | 3 | 82.3 (67.2, 91.8) |
| PPI + high-dose amoxicillin | 3 | 65.6 (56.1, 74.0) | 2 | 65.7 (51.0, 77.8) | 2 | 65.7 (51.0, 77.8) |
| BiQT | 8 | 78.4 (68.1, 86.1) | 5 | 82 (74.1, 87.8) | 1 | 87.7 (81.1, 92.2) |
| RT-DR | 1 | 83.8 (78.4, 88.0) | 1 | 83.4 (78.4, 88.0) | 1 | 83.4 (78.4, 88.0) |
| Distinct therapies | ||||
|---|---|---|---|---|
| Treatment | All countries |
Western countries |
||
| Na | Pooledb, % (95% CI) | Na | Pooledb, % (95% CI) | |
| Vonoprazan-based triple therapy | 3 | 88.2 (81.4, 92.8) | 1 | 80.8 (76.2, 84.6) |
| Vonoprazan dual therapy | 2 | 80.3 (74.5, 85.1) | 1 | 77.2 (72.3, 81.4) |
| Esomeprazole triple | 12 | 83.3 (78.1, 87.5) | 5 | 87.8 (80.6, 92.6) |
| Omeprazole triple | 23 | 78.4 (74.6, 81.8) | 11 | 77.4 (71.1, 82.7) |
| Lansoprazole triple | 17 | 78.7 (71.8, 84.3) | 4 | 83.2 (78.4, 88.0) |
| Rabeprazole triple | 15 | 83.7 (79.3, 87.3) | 1 | 76.8 (69.8, 82.7) |
| PPI + high-dose amoxicillin | 3 | 65.6 (56.1, 74.0) | 2 | 65.7 (51.0, 77.8) |
| BiQT (subsalicylate) | 1 | 70.0 (61.2, 77.5) | N/A | |
| BiQT (subcitrate) | 7 | 79.6 (68.2, 87.6) | 5 | 82 (74.1, 87.8) |
| RT-DR | 1 | 83.8 (78.4, 88.0) | 1 | 83.7 (79.3, 87.3) |
BiQT, bismuth quadruple therapy with bismuth subcitrate or bismuth subsalicylate; CI, confidence interval; PPI, proton pump inhibitor; RT-DR, rifabutin-amoxicillin-omeprazole delayed-release triple therapy.
a
Study arms.
b
Pooled (weighted) proportion meta-analysis was performed.